Capricor Therapeutics, Inc. (CAPR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $29.01: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 2.76; Below-average business quality.
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based therapies for Duchenne muscular dystrophy, with its lead asset deramiocel under FDA BLA review with a PDUFA target action date of August 22, 2026.
Sell if holding. Engine safety override at $29.01: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 2.76; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Capricor Therapeutics, Inc.
Latest news
- HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target — benzinga May 13, 2026 positive
- Capricor Therapeutics Q1 2026 Earnings Call Transcript — benzinga May 12, 2026 positive
- Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate — benzinga May 12, 2026 negative
- Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy — benzinga May 8, 2026 negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.8% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.01: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 2.76; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $26.98. Score 4.6/10, moderate confidence.
Take-profit target: $47.08 (+62.3% upside). Prior stop was $26.98. Stop-loss: $26.98.
Quality below floor (1.2 < 4.0).
Capricor Therapeutics, Inc. trades at a P/E of N/A (forward -35.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover CAPR with a consensus score of 4.1/5. Average price target: $54.
What does Capricor Therapeutics, Inc. do?Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based...
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and exosome-based therapies for Duchenne muscular dystrophy, with its lead asset deramiocel under FDA BLA review with a PDUFA target action date of August 22, 2026.